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Cutaneous anthrax outbreaks occurred in Bangladesh from August to October 2009. As part of the
epidemiological response and to conﬁrm anthrax diagnoses, serum samples were collected from suspected case
patients with observed cutaneous lesions. Anthrax lethal factor (LF), anti-protective antigen (anti-PA)
immunoglobulin G (IgG), and anthrax lethal toxin neutralization activity (TNA) levels were determined in
acute and convalescent serum of 26 case patients with suspected cutaneous anthrax from the ﬁrst and largest
of these outbreaks. LF (0.005–1.264 ng/mL) was detected in acute serum from 18 of 26 individuals. Anti-PA
IgG and TNA were detected in sera from the same 18 individuals and ranged from 10.0 to 679.5 lg/mL and 27
to 593 units, respectively. Seroconversion to serum anti-PA and TNA was found only in case patients with
measurable toxemia. This is the ﬁrst report of quantitative analysis of serum LF in cutaneous anthrax and the
ﬁrst to associate acute stage toxemia with subsequent antitoxin antibody responses.
Anthrax is a zoonotic disease caused by the gram
positive bacterium Bacillus anthracis. The disease is
primarily associated with herbivores and domestic
livestock and occurs with regularity in countries where
widespread vaccination of animals is not practiced
(http://www.promedmail.org). Human anthrax is less
common and usually occurs subsequent to handling
infected domestic animals including cattle and goats or
their products (eg, skin, meat, hides, and bones). There
are 3 primaryforms of the disease in humans; cutaneous
(CA), gastrointestinal (GA), and inhalation (IA),
dependingontherouteofexposuretoBacillusanthracis.
The case-fatality rate in humans for untreated anthrax
ranges from 20% for CA, to 25%–60% for GA and
86%–89% for IA (http://www.bt.cdc.gov/agent/anthrax/
faq/signs.asp)[ 1]. The case-fatality rate for IA in the
2001 anthrax letter attacks in the United States was 45%
even with antimicrobial treatment and aggressive sup-
portive patient care [2, 3].
The pathogenesis of anthrax is primarily attributed to
the protein exotoxins, lethal toxin (LTx) and edema toxin
(ETx), secreted by B. anthracis. LTx has been shown to be
sufﬁcient to cause death in a variety of animal models.
The pivotal protein of these toxins is the ‘‘protective an-
tigen’’ (PA) that binds to enzymatic components lethal
factor (LF) and edema factor (EF) [4]a n dt r a n s p o r t s
them into host target cells. LF is a zinc-dependent en-
doproteinase that hydrolyzes and inactivates at least
5 members of the mitogen-activated protein kinase kinase
(MAPKK) family of response regulators involved in
immune activation [5]. EF is a calmodulin dependent
adenylate cyclase that converts adenosine triphosphate
(ATP) to cyclic adenosine monophosphate (cAMP) [6].
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responses. The combined effects of the toxins are local necrosis
and edema in cutaneous anthrax, and hemorrhagic medias-
tinal necrosis, hypoxic insult and pleural edema in inhalation
anthrax [7]. A consequence of the combined activities of these
toxins is to inhibit innate and acquired immune responses
thus facilitating the extensive bacterial proliferation of sys-
temic anthrax [4]. Protection against anthrax is mediated by
antitoxin antibody responses whether actively induced or
passively administered.
Due to the low frequency of occurrence of natural anthrax in
humans, there are only limited data available on the human im-
mune response to B. anthracis infections and in particular for CA
[8]. In the present study, sensitive and speciﬁc LF quantiﬁcation,
anti-PA immunoglobulin G (IgG) and toxin neutralization as-
says were used in an evaluation of acute and convalescent sera
from 26 suspected human CA cases from an outbreak reported
in North-Western Bangladesh between August and October
2009 [9, 10, 11, 12].
LF was present in acute serum from CA cases and after an-
timicrobial treatment. Anti-PA and TNA were observed only in
convalescent sera from individuals with measureable LF. The
data indicate that in cases of conﬁrmed cutaneous anthrax,
toxinsaresecretedintothebloodinducinganantitoxinimmune
response. Anti-PA IgG levels in naturally acquired CA were
statistically signiﬁcantly higher than those reported for bio-
terrorism associated CA.
MATERIALS AND METHODS
Materials
All chemicals and reagents were obtained from Sigma-Aldrich
except where indicated.
Case Definitions
Case patients for evaluation occurred from the date of slaugh-
tering the ﬁrst sick animal on August 18th in the outbreak area
until 3 weeks after the last sick animal was slaughtered. Anthrax
cases were deﬁned as suspect (possible), probable (presumptive),
or conﬁrmed according to the following criteria. Suspect CA
was deﬁned as acute onset of a painless skin lesion(s) that de-
veloped over 2–6 days from a papular through a vesicular stage
to skin ulceration with raised margin and central black eschar.
ProbableCAwasdeﬁned bythe presenceofa documentedlesion
accompanied by an epidemiological link to either a known ex-
posure or a positive result for LF toxemia. Conﬁrmed CA was
deﬁned by the presence of a cutaneous anthrax lesion accom-
panied by one or more of the following: positive identiﬁcation
of B. anthracis by growth in culture, M’Fadyean (MFad) stain,
immunohistochemical (IHC) stain, or evidence of a 4-fold
change in anti-PA IgG antibody levels between acute and con-
valescent sera or paired convalescent sera. For acute sera that were
nonreactive by anti-PA ELISA, the assay lower limit of quan-
tiﬁcation (LLOQ) was used to determine 4-fold change. Serum
toxin neutralization activity (TNA) measurements were not
included in the case deﬁnition. Serum TNA provides an as-
sessment of the functional activity of anti-PA antibodies,
and enhances the diagnostic sensitivity and speciﬁcity of the
anti-PA IgG.
Human Cutaneous Anthrax
Cutaneous anthrax cases were deﬁned as described above. Re-
ported exposures consisted of but were not limited to one or
more of the following: handled raw meat, contacted sick animal,
contacted dead animal, and/or was present close to the slaugh-
teringsite.Acute andconvalescentserafrom26suspectCAcases
were obtained as part of the Government of Bangladesh, In-
ternational Centre of Diarrhoeal Disease Research, Bangladesh
(ICDDR, B) and Centers for Disease Control and Prevention
(CDC)responsetothe2009outbreak.Acutestageserumsamples
were those collected when cutaneous lesions were ﬁrst identiﬁed;
convalescent stage sera were those collected 16–28 days after
appearance of the lesions. Antimicrobial treatment with ci-
proﬂoxacin commenced prior to or on the date of acute sample
collection (Table 1). Swabs of vesicles were obtained for bac-
terial culture when feasible. In case patients where swabs were
not collected, the vesicles were either dry or insufﬁciently de-
veloped. The details of this anthrax outbreak epidemiology,
management and informed consent are described elsewhere
(Chakraborty et al 2011, submitted).
Serological Methods
Sera were collected using serum separation tubes (SST) (Becton
Dickinson). Detailed methods for quantiﬁcation of LF, anti-PA
IgG, and TNA are described elsewhere [10, 11, 12, 13]. LF
toxemia was quantiﬁed using a validated mass spectrometry
(LF-MS) methodthat reportsspeciﬁcLFendoproteinaseactivity
in ng/mL of serum [10]. The LF-MS assay had precision of
8%–14%,accuracyof92%–98%,and100%diagnosticsensitivity
and speciﬁcity (M. Gallegos, unpublished data).
Anti-PA IgG was measured by enzyme-linked immuno-
sorbent assay (ELISA) and reported in lg/mL [12]. The anti-
PA ELISA had a diagnostic sensitivity of 99.8% and diagnostic
speciﬁcity of 98.4%. As case patients were symptomatic at the
time of earliest serum acquisition and actual exposure times
were not determined, seroconversion was deﬁned as a $4-fold
increase in anti-PA IgG concentration in the convalescent
serumcomparedwiththeacuteserum.Ifanacuteserumwasnot
available or was obtained later than 7 days after symptoms onset,
seroconversion was deﬁned as a $4-fold increase over the assay
lower limit of quantiﬁcation (LLOQ, 3.7 lg/mL).
The TNA assay measured the ability of a test serum to neu-
tralize lethal toxin mediated killing of the macrophage cell
line J774A.1 [11]. The primary endpoint used in this study was
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neutralization of anthrax lethal toxin cytotoxicity (ED50). The
TNA assay had a LLOQ ED50 titer of 36 with 97% diagnostic
sensitivity and 100% diagnostic speciﬁcity [8].
M'Fadyean Stain, Immunohistochemistry, and Culture Isolation
Culture analysis, M’Fadyean staining (MFad) of capsule, and
immunohistochemistry (IHC) staining of cell wall and capsule
antigens for detection of B. anthracis in lesion swabs, vesicle
smears, and skinbiopsieswere performedasdescribed elsewhere
[14, 15, 16].
RESULTS
Serum samples from 26 suspected CA cases were evaluated for
LF toxemia, seroconversion to anti-PA IgG and serum toxin
neutralization activity (TNA) and compared with culture and
direct observation diagnostic tests for anthrax. Acute stage
samples were collected from 1 to 14 days after symptom onset
Table 1. B. anthracis Was Detected by Culture (Cult) of Lesion Swabs, M'Fadyean Staining (MFad) of Lesion Smears, and
Immunohistochemistry (IHC) of Tissue Biopsies, Indicated by 1 (Positive), – (Negative), or NS (No Sample)
Acute Convalescent
Case ID
Antimicrobials
pre-acute
(days)
Acute
post-onset
(days)
Conv.
post-onset
(days)
BA conﬁrmed
by culture,
IHC, or MFad
Anti-PA
(lg/mL)
TNA
(ED50)
LF
(ng/mL)
Anti-PA
(lg/mL)
TNA
(ED50)
LF
(ng/mL)
$4-fold
change
in anti-PA
Diagnostic
status
pab1 2 8 28 1 (IHC) ,LLOQ 0 0.996 47.4 147 ,LOD Yes Conﬁrmed
pab2 3 8 28 2 ,LLOQ 0 0.943 78.8 438 ,LOD Yes Conﬁrmed
pab3 0 8 28 1 (IHC) 4.9 0 0.041 44.1 27 NA Yes Conﬁrmed
pab4 0 8 28 NS ,LLOQ 0 0.069 88.0 93 ,LOD Yes Conﬁrmed
pab5 2 8 28 1 (IHC) ,LLOQ 0 1.264 55.9 109 ,LOD Yes Conﬁrmed
pab7 3 7 27 2 ,LLOQ 0 0.310 230.6 593 NA Yes Conﬁrmed
pab8 0 7 27 2 ,LLOQ 0 0.011 26.8 0 ,LOD Yes Conﬁrmed
pab9 7 7 27 2 ,LLOQ 0 0.161 42.8 189 ,LOD Yes Conﬁrmed
pab10 5 7 27 2 ,LLOQ 0 1.166 76.0 80 ,LOD Yes Conﬁrmed
pab11 7 7 27 2 ,LLOQ 0 0.031 21.1 39 ,LOD Yes Conﬁrmed
pab12 0 7 27 1 (MFad) ,LLOQ NS 0.159 55.9 104 ,LOD Yes Conﬁrmed
pab13 0 6 26 2 ,LLOQ 0 0.675 83.5 88 ,LOD Yes Conﬁrmed
pab14 0 3 23 2 ,LLOQ 0 0.040 10.0 40 NA No Conﬁrmed*
pab15 0 3 23 2 19.1 0 0.005 85.8 65 ,LOD Yes Conﬁrmed
pab16 0 1 21 NS ,LLOQ 0 ,LOD ,LLOQ 0 ,LOD No Probable
pab18 0 8 28 1 (Cult/Mfad) ,LLOQ 0 0.486 144.8 277 ,LOD Yes Conﬁrmed
pab19 0 7 27 2 ,LLOQ 0 ,LOD ,LLOQ 0 NA No Probable
pab20 0 6 25 1/2 (MFad) ,LLOQ 0 ,LOD 4.0 0 ,LOD No Probable
pab21 0 3 22 1 (Cult/MFad) ,LLOQ 0 1.105 194.0 83 ,LOD Yes Conﬁrmed
pab23 0 5 24 NS ,LLOQ 0 ,LOD ,LLOQ 0 NA No Probable
pab25 0 1 20 NS ,LLOQ 0 ,LOD ,LLOQ 0 ,LOD No Probable
pab27 0 1 20 NS ,LLOQ 0 ,LOD ,LLOQ 0 ,LOD No Probable
pab29 5 5 16 2 ,LLOQ 0 ,LOD ,LLOQ 0 NA No Probable
pab30 5 5 16 NS ,LLOQ 0 ,LOD ,LLOQ 0 ,LOD No Probable
pab31 4 5 16 2 4.0 0 0.035 12.3 45 ,LOD No Conﬁrmed*
pab32 4 14 25 2 679.5 58 0.086 487.2 241 NA No Conﬁrmed*
GMC of
positive
results
5.0 24.0 22.5
a 0.153 48.1 107.92
SE 0.14 0.04 2.3 0.511 0.28 0.23
Conﬁrmed indicates the presence of cutaneous lesion with one of the following: culture, IHC, MFad, or $4-fold change in anti-PA titer over the lower limit of
quantiﬁcation (3.7 lg/mL) or $4-fold change in anti-PA titer between paired acute and convalescent serum samples. Conﬁrmed* refers to case patients that exhibit
elevated convalescent anti-PA that do not meet the $4-fold change from the acute sample but that exhibit a $4 fold change in TNA. Probable refers to case patients
that exhibited cutaneous anthrax-like lesions and an epi-link to exposure.
Abbreviations: Anti-PA, anti-protective antigen; BA, B. anthracis; GMC, geometic mean concentration; LF, lethal factor; LLOQ, lower limit of quantiﬁcation; LOD,
limit of detection; NA, insufﬁcient sample volume available for all measurements; SE, standard error of the mean; TNA, toxin neutralization activity.
a The acute stage anti-PA GMC was higher than expected because the immune response to infection for pab32 had passed its peak level and exposure may have
been earlier than assessed from the development of the cutaneous lesion.
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crobial use was reported in 11 individuals from 2 to 7 days prior
to collection of the ﬁrst available (acute) sample. In the re-
maining 15 case patients, antimicrobial treatment commenced
with the acute sample collection (Table 1).
Ofthe 26suspected CAcases inthis study, there were6 (pab4,
pab16, pab23, pab25, pab27, and pab30) for which a sample was
not available for analysis by culture/IHC/M’Fadyean (culture/
observation) (Table 1). Of the 20 case patients for which a lesion
sample was available, 6 (pab1, pab3, pab5, pab12, pab18, and
pab21) were conﬁrmed by culture/IHC/M’Fadyean (Figures 1
and 2). Serum from these 6 individuals was also reactive for LF
toxemia, anti-PA IgG, and serum TNA. The LF concentrations
for these6 CAcasesranged from0.041to1.26ng/mL.There was
not a consistent trend between the magnitude of toxemia and
eschar reactivity by culture/IHC/M’Fadyean. One case patient
(pab20) that was indeterminate by culture/IHC/M’Fadyean was
nonreactive by any test except the anti-PA IgG ELISA. However,
this individual was classiﬁed as indeterminate as there was not
a 4-fold increase in anti-PA IgG between acute (,LLOQ) and
convalescent (4.0 lg/mL) sera. There were 13 case patients
(pab2, pab7, pab8, pab9, pab10, pab11, pab13, pab14, pab15,
pab19, pab29, pab31,and pab32) for which there was a sample
available but that were by negative for culture observation by
either culture, IHC or M’Fadyean.
Twelve case patients (pab2, pab4, pab7, pab8, pab9, pab10,
pab11, pab13, pab14, pab15, pab31, and pab32) were reactive by
toxemia and serology only (Table 1). Three of these (pab14,
pab31, and pab32) were reactive but did not meet the required
4-fold change between acute and convalescent paired sera for
anti-PA and 1 (pab8) did not meet the $4-fold increase re-
quired for TNA reactivity. For pab14 and pab31, anti-PA IgG
levels increased from ,LLOQ to 10 lg/mL and from 4.0 lg/mL
to 12.3 lg/mL between acute and convalescent sera, respectively.
Thus, they did not meet the criterion for seroconversion. Pab32
hada highlevelofanti-PAIgG in the acuteserum(679.5lg/mL)
and convalescent serum (487.2 lg/mL) and therefore also did
not achieve a 4-fold change in anti-PA required for serocon-
version. Serum TNA for these 3 cases increased from ,LLOQ
to an ED50 titer of 40 and 45 for pab14 and pab31, respectively,
and from 58 to 487.2 for pab32. LF levels in pab14, pab31 and
pab32 were 0.040, 0.035, and 0.086 ng/mL, respectively. Case
pab8, although not reactive by TNA assay, had measureable
levels of both LF (0.11 ng/mL) and anti-PA antibody (conva-
lescent, 26.8 lg/mL), indicating that this also was a true in-
fection. The combined data from all 3 serological tests indicate
that these were true infections.
Four case patients (pab3, pab15, pab31, and pab32) had de-
tectable levels of anti-PA IgG in their acute stage sera. Acute
stage samples for pab3, pab15, and pab31 were obtained at days
8, 3, and 5 after reported onset of symptoms, respectively. The
onset of an anti-PA antibody response in these 4 individuals was
earlier than the day 12 onset reported previously for bioterror-
ism associatedcutaneousanthrax[8].The acutestagesamplefor
pab32wasobtainedatday14andhadahighlevelofanti-PAIgG
(679.5 lg/mL), which declined to 487.2 lg/mL in the conva-
lescent serum (day 25). This demonstrates that the immune
response to infection had passed its peak level and that exposure
may have been considerably earlier than assessed from the de-
velopment of the cutaneous lesion. Of note is that this was the
onlycase forwhichanacute serum samplehada detectableTNA
titer and the titer increased $4-fold as discussed above. Linear
regression analysis indicated a positive correlation (r
2 5 0.41)
between log10 transformed TNA ED50 titer and anti-PA IgG
Figure 1. IHC staining of abundant granular and bacilliform antigens in
skin biopsy samples with anti–B. anthracis capsule antibody (A) and
anti–B. anthracis cell wall antibody (B). Immunoalkaline phosphatase
with napthol fast red substrate and hematoxylin counterstain. Original
magnifications: 400X.
Figure 2. M'Fadyean (MFad) stain for capsulated B. anthracis in
a cutaneous lesion smear (pab21). The pink-stained poly-D-glutamic acid
(PGA) capsule can be seen surrounding the purple stained vegetative
bacilli.
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is lower than that reported previously for inhalation anthrax
(r
2 5 0.83). The reason for this difference is unclear and may be
a consequence of the different disease presentations. Of partic-
ular interest to note is that no convalescent stage sample con-
tained detectable LF and all case patients that seroconverted to
anti-PA had detectable acute stage toxemia.
There are few opportunities to compare laboratory diagnostic
data for human anthrax. We compared the anti-PA responses
for naturally acquired CA in this study with those previously
reported for bioterrorism (BT) associated CA [8]. The BT and
naturally acquired CA samples were evaluated using the same
validated anti-PA ELISA, reference standards, and QC criteria.
The long-term performance stability of this assay has also been
described [17] and provides conﬁdence in the comparison.
Comparisons were made using ﬁrst the Shapiro-Wilk statistic
test for normality, followed by the t test for normally distributed
data. Both the bioterrorism-acquired and the naturally acquired
maximum anti-PA IgG values were normally distributed in log
space. The maximum measured anti-PA IgG level was signiﬁ-
cantly lower in BT associated CA than in naturally acquired CA
(25.0lg/mL[n513]vs52.6lg/mL[n521][P 5.046,2-sided
unequal variance] (Figure 4).
DISCUSSION
More than 95% of all naturally occurring B. anthracis infections
reported worldwide are cutaneous [7]. Cutaneous anthrax is
associated with handling infected animals or contaminated
items such as meat, wool, hides, leather, or hair products from
infected animals [18]. Historically, case-fatality rates for this
form of the disease are 20% without treatment and ,1% with
appropriate antimicrobial therapy [19]. The human serum
s a m p l e si nt h i ss t u d yw e r ea l lf r o ms u s p e c tc u t a n e o u sa n t h r a x
cases associated with handling infected cattle and goats. Anthrax
was conﬁrmed by detection of B. anthracis in cutaneous lesions
by culture, immunohistochemistry (IHC), and M’Fadyean stain-
ing (MFad). There were no fatalities (Chakraborty et al, sub-
mitted).
Standard diagnostic protocols for cutaneous anthrax include
culture from vesicular ﬂuid, swabs, or punch biopsy of the le-
sion. Culture from blood samples is recommended only if the
patient has evidence of systemic anthrax and has not received
antimicrobial agents (http://www.bt.cdc.gov/agent/anthrax/lab-
testing/recommended_specimens.asp)[ 20]. The value of sero-
logical tests, including anti-LF antibody measurements, as ret-
rospective diagnostic or epidemiologic tools in studies of
cutaneous, gastrointestinal, and inhalation anthrax is well es-
tablished [3, 8, 12, 19, 21, 22, 23]. However, the evaluation of
toxemia in human cutaneous anthrax has not to our knowledge
been previously reported. The mass spectrometry-based method
used in this study for quantitative determination of LF toxemia
is gaining increasing prominence as a high throughput, high
sensitivity diagnostic tool [10, 24]. This method can provide
conﬁrmatory diagnosis up to 24 hours earlier than other
methods in animal models and can detect and quantify LF for
12-days post-antimicrobial therapy and 7 days post-anthrax
immune globulin intravenous (AIGIV) treatment in human
clinical samples [13, 22]. The persistence of LF in serum after
clearance of bacteremia by antimicrobial treatment is a key
advantage of this method. Of particular interest from this
study is that in all cutaneous anthrax cases conﬁrmed by at least
1 other diagnostic test, LF toxemia was detectable up to day 14
after symptom onset (pab32) but was absent in all convalescent
sera the earliest of which was obtained on day 16.
Figure 3. Linear regression analysis of log10 TNA ED50 titers with log10
anti–protective antigen (anti-PA) immunoglobulin G (IgG) (lg/mL) for all
values greater or equal to the assays' lower limits of quantification indicated
a positive correlation (r
25 0.41). In humans, PA is a major toxin neutralizing–
antibody determinant for both cutaneous and inhalation anthrax.
Figure 4. Box Plot comparisons of maximum determined anti–
protective antigen (anti-PA) immunoglobulin G (IgG) responses from
bioterrorism (BT) associated and naturally occurring cutaneous anthrax
cases. Geometric means are 25.0 lg/mL (n 5 13) and 52.6 lg/mL
(n 5 21) respectively, which are statistically significantly different
(P 5 .046). Comparisons were made using first the Shapiro-Wilk statistic
test for normality, followed by the t test for normally distributed data.
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infection, because exposure to toxin requires spore germination
and vegetative cell growth. This is demonstrated by the current
data where all case patients that seroconverted also had detect-
abletoxemia in theiracute stage sera. Asindicated for pab32,the
magnitude of the antibody response and changes between acute
and convalescent sera may be indicative of the onset of disease
and need not always be concurrent with onset of discernable
symptoms. In human cutaneous anthrax the peak anti-PA IgG
response levels are considered to be signiﬁcantly lower and take
longer to develop than in inhalation anthrax [8]. In this study
the maximum anti-PA antibody levels were signiﬁcantly higher
than those reported previously for bioterrorism associated cu-
taneous and inhalation anthrax. This may be a consequence of
the different types of exposure to B. anthracis, the naturally
acquiredcasespotentiallyhaving agreaterdegreeofcontactwith
more heavily contaminated materials.
The validated toxin neutralization assay (TNA) measures the
ability of the antibodies present in serum to neutralize lethal toxin
activity on a macrophage cell line [11]. Toxin neutralization ac-
tivity (TNA) was observed only in sera from which anti-PA IgG
was quantiﬁable by ELISA. In this study there was only a very low
correlation (r
2 5 0.42) between serum anti-PA IgG concentration
(lg/mL) and TNA ED50, which is in contrast to previous reports
for bioterrorism associated inhalation anthrax [8]. The reason for
these differences is not known, but it is tempting to speculate
that it is related to the type of exposure and a lower level of
antigen load that elicits production of lower afﬁnity antibody
that is less efﬁcient at toxin neutralization. The single case
patient (pab8) that was conﬁrmed by at least 2 other tests but did
not have detectable TNA is conﬁrmation that 100% diagnostic
sensitivity for an antibody-based diagnostic test for anthrax re-
mains elusive. However, it must also be noted that in this study at
least, the anti-PA ELISA produced no false positive or false neg-
ative results and only 1 indeterminate result.
In this study only 6 of 20 biopsy samples tested positive for the
presence of B. anthracis by culture, M’Fadyean stain of vesicle/
l e s i o ns m e a r s ,o rI H C .T h i sm a yb ed u ei np a r tt ot h eu s eo f
antimicrobial therapy since 8 case patients with negative results
had received antimicrobial therapy from 3 to 7 days prior to
sample collection. In contrast, both acute LF and convalescent
anti-PA were positive in 18 samples of which 9 had received an-
timicrobial agents from 2 to 7 days prior to ﬁrst sample collection,
showing little interference from antimicrobial use as observed
previously [2, 22].
T h e s er e s u l t sc o l l e c t i v e l yi n d i c a t et h a tw h i l et h ei n f e c t i o nm a y
remain localized to the lesion during early cutaneous infection, in
most cases toxins are secreted into the blood in sufﬁcient quantity
tobemeasured andsubsequently induceeffectivetoxinneutralizing
antibody responses. This study reports the ﬁrst documented evi-
dence of measureable anthrax toxin LF in the blood during
clinical cutaneous anthrax and illustrates a direct association of
the presence of LF and the subsequent development of anti-PA
and TNA. These results conﬁrm the value of serological
measurements for conﬁrmation of anthrax, when B. anthracis
cannot be cultured or visualized by staining methods.
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